The effect of lipegfilgrastim on hematopoietic reconstitution and supportive treatment after megachemotherapy with autologous peripheral blood stem cell transplantation in patients with lymphoproliferative malignancies
Journal Title: OncoReview - Year 2016, Vol 6, Issue 2
Abstract
Megachemotherapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) is a standard treatment option in patients below 70 years of age with multiple myeloma (MM) as well as with relapsed and refractory lymphomas. Recombinant granulocyte colony-stimulating factors (G-CSF) are commonly used to accelerate bone marrow recovery after chemotherapy and reduce the duration of severe neutropenia. Lipegfilgrastim is a glicopegylated G-CSF with prolonged action registered for adult patients with malignant neoplasms in order to reduce the duration of neutropenia and the incidence of febrile neutropenia (FN). So far, there is not enough data to confirm the effectiveness and safety of this drug in patients with hematological malignancies including those undergoing auto-PBSCT. The aim of this study was to determine the effect of lipegfilgrastim on hematopoietic regeneration and supportive care after auto-PBSCT in patients with lymphoproliferative malignancies. The study population consisted of 30 patients (12 female and 18 male; median age: 50 years ± 13), including 13 patients with MM, 5 with Hodgkin’s lymphoma (HL) and 12 with non-Hodgkin’s lymphoma (nHL). The median number of transplanted CD34+ cells was 3.96 ± 1.56 × 10^6/kg of body mass. On day +1 after auto-PBSCT, the patients received lipegfilgrastim in a single 6 mg subcutaneous injection. The control group consisted of 32 patients (13 female and 19 male; median age: 50 years ± 6.4), including 13 with MM, 8 with HL and 11 with nHL, who received subcutaneous filgrastim in a dose of 5 μg/kg/day from day +1 after transplantation and continued to an absolute neutrophil count (ANC) > 1.5 × 10^9/L. There was no significant difference in the time of regeneration ANC > 0.5 × 10^9/L which was 10.65 ± 1.00 vs. 11.51 ± 2.29 days respectively in the study and control group. Similar observations were noted regarding the duration of febrile neutropenia (2.16 ± 2.22 vs. 1.70 ± 4.17 days; p = 0.998), regeneration of platelets (PLT) > 20 × 10^9/L (12.41 ± 2.41 vs. 13.82 ± 4.48 days; p = 0.233) and demand for transfusion of red blood cells (0.76 ± 1.07 vs. 1.33 ± 2.33 units; p = 0.414) and platelets (11.5 ± 6.9 vs. 19.2 ± 17.7 units; p = 0.08). Different results were observed for the length of hospitalization, which was significantly shorter in the lipegfilgrastim group (16.14 ± 14 vs. 24.46 ± 6.79 days; p = 0.000). Lipegfilgrastim is as effective as filgrastim with regards to the regeneration of the hematopoietic system, duration of febrile neutropenia, demand for transfusion of blood products and significantly reduces hospitalization in patients with lymphoproliferative malignancies after auto-PBSCT.
Authors and Affiliations
Ewa Frączak, Jarosław Dybko, Justyna Rybka, Monika Biedroń, Izabela Dereń-Wagemann, Donata Urbaniak-Kujda, Kazimierz Kuliczkowski, Tomasz Wróbel
Keywords
Related Articles
- EP ID EP78743
- DOI 10.5604/20828691.1207984
- Views 182
- Downloads 0
Dermatofibrosarcoma protuberans (DFSP) – advances in diagnostics and therapy
Dermatofibrosarcoma protuberans is a rare soft tissue sarcoma with a superficial growth. It has an estimated incidence of 4 cases per one million persons per year. DFSP is preferentially located on the trunk. It can appe...
Nuclear medicine diagnostic tools for early detection of myocardial damage in treated breast cancer patients
The most severe side effect in treated patients with breast cancer is treatment-induced cardiotoxicity, leading to chronic heart failure or CAD, and worsening the patient’s quality of life. The early detection and medica...
Przydatność kliniczna pomiaru liczby krążących komórek nowotworowych u chorych na raka piersi
Wstęp: Monitorowanie raka piersi po leczeniu adiuwantowym w szczególnych przypadkach może się opierać na zastosowaniu metod obrazowych lub wykonaniu biopsji. W świetle obecnych badań należy zadać pytanie, czy alternatywn...
„D-dimeroza” u chorych z chorobą nowotworową, czy zawsze wymaga leczenia?
W chorobie nowotworowej wzrasta ryzyko żylnej choroby zakrzepowo-zatorowej. D-dimery są produktem degradacji fibryny i ich stężenie wzrasta w nowotworach, a także w wielu innych stanach klinicznych, w których dochodzi do...
Percutaneous vena cava superior angioplasty and stenting as an effective method of treatment in vena cava superior syndrome in the course of lung cancer
Vena cava superior syndrome (VCSS) is a sudden life-threatening condition encountered in patients with neoplasms. The prognosis depends on histopathological diagnosis, severity of clinical symptoms and administered treat...